Colin Smith

Title: Colin Smith - Innovator in CNS Activity Compounds

Introduction

Colin Smith is a notable inventor based in New Malden, GB. He has made significant contributions to the field of pharmacology, particularly in the development of compounds with central nervous system (CNS) activity. His work focuses on innovative solutions for anxiety and Parkinson's disease.

Latest Patents

Colin Smith holds a patent for his invention titled "Anti-anxiety and anti-parkinsonian - 1-Aminoethyl, 1-aminopropyl and 1-aminobutyl derivatives of 7,7-dimethylnorbornane." This patent describes various derivatives that include amino groups, which can be optionally substituted by alkyl groups or saturated heterocyclic amino groups. The alkylene group at the 1-position can also be substituted, and the 2-position can be substituted by chlorine. These compounds exhibit CNS activity, showcasing their potential therapeutic benefits.

Career Highlights

Colin Smith is associated with Glaxo Laboratories Limited, where he has been instrumental in advancing research and development in pharmacological compounds. His expertise and innovative approach have contributed to the company's reputation in the pharmaceutical industry.

Collaborations

Colin has collaborated with Leslie Stephenson, working together to enhance the understanding and application of CNS-active compounds. Their partnership has fostered a productive environment for innovation and research.

Conclusion

Colin Smith's contributions to the field of pharmacology, particularly through his patent on CNS-active compounds, highlight his role as an innovator. His work continues to pave the way for advancements in treatments for anxiety and Parkinson's disease.